AGP Executive Report
Last update: 4 hours agoBiotech Deal: Novartis (Basel) signed a licensing deal worth up to $7.8B with China’s Abogen Biosciences for an early-stage mRNA autoimmune therapy (ABO2203), including a $575M upfront and up to $7.2B in milestones, giving Novartis exclusive worldwide rights. Developer Infrastructure: Zurich-founded Namespace raised €37M/$42M Series B to speed up developer compute for AI agents, CI, builds and testing across Mac/Windows/Linux, bringing total funding to $65M. AI Admin Tools: Agence MAO launched its AI virtual assistant suite internationally for French-speaking tradespeople and small businesses, with modules for calls, scheduling, quotes, invoicing and accounting (claims GDPR/nFADP compliance). Health Research: A study reports regular walking helps COPD patients even in polluted environments, easing symptom flare-ups regardless of air quality. Life Sciences Partnerships: CSL agreed to co-develop and co-promote lixudebart with Swiss biotech Alentis in a deal up to $1.6B for rare kidney and liver diseases. Climate & Glaciers: Switzerland’s Alps continue to take hits as glaciers shrink fast; one report highlights Slovenia’s Triglav glacier could vanish within days. Switzerland–India Tech & Trade: India and Switzerland moved to expand TEPA-related market access and cooperation, including innovation and technology transfer, alongside defence and nuclear energy talks.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
